CVS Health Corporation $CVS Shares Purchased by MASTERINVEST Kapitalanlage GmbH

MASTERINVEST Kapitalanlage GmbH raised its holdings in CVS Health Corporation (NYSE:CVS) by 99.8% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 16,211 shares of the pharmacy operator’s stock after buying an additional 8,098 shares during the period. MASTERINVEST Kapitalanlage GmbH’s holdings in CVS Health were worth $1,164,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Sei Investments Co. grew its position in shares of CVS Health by 17.4% during the second quarter. Sei Investments Co. now owns 905,715 shares of the pharmacy operator’s stock worth $62,474,000 after buying an additional 134,535 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in CVS Health by 1.2% in the second quarter. The Manufacturers Life Insurance Company now owns 1,121,377 shares of the pharmacy operator’s stock valued at $77,353,000 after acquiring an additional 13,329 shares during the last quarter. Treasurer of the State of North Carolina boosted its stake in CVS Health by 1.3% in the second quarter. Treasurer of the State of North Carolina now owns 585,073 shares of the pharmacy operator’s stock valued at $40,358,000 after acquiring an additional 7,588 shares in the last quarter. HUB Investment Partners LLC boosted its stake in CVS Health by 25.0% in the second quarter. HUB Investment Partners LLC now owns 15,063 shares of the pharmacy operator’s stock valued at $1,039,000 after acquiring an additional 3,011 shares in the last quarter. Finally, Alliancebernstein L.P. grew its holdings in shares of CVS Health by 8.0% during the second quarter. Alliancebernstein L.P. now owns 1,609,404 shares of the pharmacy operator’s stock worth $111,017,000 after purchasing an additional 119,439 shares during the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the transaction, the executive vice president owned 10,133 shares in the company, valued at $907,714.14. This trade represents a 87.28% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Larry Robbins sold 1,983,538 shares of the business’s stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total transaction of $187,345,164.10. Following the sale, the director directly owned 6,213,261 shares in the company, valued at approximately $586,842,501.45. This represents a 24.20% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 3,441,551 shares of company stock worth $323,703,977. Corporate insiders own 0.85% of the company’s stock.

Analysts Set New Price Targets

CVS has been the subject of several research reports. Cantor Fitzgerald boosted their target price on CVS Health from $100.00 to $110.00 and gave the company an “overweight” rating in a report on Tuesday, July 7th. Barclays raised their price target on CVS Health from $101.00 to $106.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 26th. Robert W. Baird boosted their price objective on CVS Health from $92.00 to $94.00 and gave the company an “outperform” rating in a research note on Wednesday, April 15th. Royal Bank Of Canada increased their price objective on CVS Health from $107.00 to $113.00 and gave the company an “outperform” rating in a report on Thursday, July 9th. Finally, Deutsche Bank Aktiengesellschaft raised their target price on shares of CVS Health from $88.00 to $92.00 and gave the stock a “buy” rating in a research report on Thursday, May 7th. Twenty-one research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $105.38.

Key CVS Health News

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Truist Financial raised its price target on CVS to $118 and reiterated a buy rating, reinforcing bullish analyst sentiment and suggesting additional upside from current levels.
• Positive Sentiment: CVS Caremark reached a global settlement with the FTC that CVS says advances transparency and affordability in prescription drug pricing, potentially easing a major legal overhang for the pharmacy-benefit manager business. Article Title
• Positive Sentiment: Reports highlighting CVS as a 52-week high stock and a potentially attractive long-term value play are keeping momentum traders and value investors interested.
• Neutral Sentiment: CVS continued to promote Aetna provider survey results showing improved payer trust and the benefits of digital tools, which is supportive for the healthcare-services narrative but not a major immediate stock catalyst. Article Title
• Neutral Sentiment: CVS also affirmed its dividend and expanded GLP-1 support programs, which helps the investment case, though the market may still be waiting to see whether those efforts meaningfully improve employer economics and utilization trends.
• Negative Sentiment: Wall Street Zen downgraded CVS to Hold, and the stock is trading near its recent high, which could prompt some investors to question near-term valuation after a strong run.

CVS Health Stock Performance

Shares of CVS stock opened at $106.01 on Thursday. The company has a current ratio of 0.87, a quick ratio of 0.66 and a debt-to-equity ratio of 0.78. The stock has a 50 day simple moving average of $98.25 and a 200-day simple moving average of $84.79. The company has a market cap of $135.26 billion, a price-to-earnings ratio of 46.70, a price-to-earnings-growth ratio of 1.04 and a beta of 0.61. CVS Health Corporation has a 12-month low of $58.50 and a 12-month high of $107.94.

CVS Health (NYSE:CVS) last posted its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share for the quarter, beating analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The firm had revenue of $100.43 billion for the quarter, compared to the consensus estimate of $94.99 billion. During the same period in the previous year, the business earned $2.25 earnings per share. The company’s revenue for the quarter was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, equities analysts forecast that CVS Health Corporation will post 7.46 EPS for the current year.

CVS Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, August 3rd. Stockholders of record on Thursday, July 23rd will be paid a dividend of $0.665 per share. The ex-dividend date of this dividend is Thursday, July 23rd. This represents a $2.66 dividend on an annualized basis and a dividend yield of 2.5%. CVS Health’s dividend payout ratio is 117.18%.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.